PLOS is a non-profit organization on a mission to drive open science forward with measurable, meaningful change in research publishing, policy, and practice.

Building on a strong legacy of pioneering innovation, PLOS continues to be a catalyst, reimagining models to meet open science principles, removing barriers and promoting inclusion in knowledge creation and sharing, and publishing research outputs that enable everyone to learn from, reuse and build upon scientific knowledge.

We believe in a better future where science is open to all, for all.

Journals
More Content
PLOS BLOGS Speaking of Medicine and Health
Browse all PLOS Blogs
Browse all PLOS Blogs

This Week in PLoS Medicine: Economic growth in India; Predictions from translational trials

Michael Morris General

Image Credit: Gopal Vijayaraghavan

Three new articles were published this week in PLoS Medicine, with a Perspective on one research article.

An analysis of cross-sectional data from repeated household surveys in India, combined with data on economic growth, fails to find strong evidence that recent economic growth in India is associated with a reduction in child undernutrition.

Jonathan Kimmelman and Alex London argue that ethical reviewers and decision-makers pay insufficient attention to threats to validity in pre-clinical studies and consult too narrow a set of evidence.

James Lavery provides feedback from the point of view of Institutional Review Boards (IRBs) on a proposal by Jonathan Kimmelman and Alex London and how IRBs might better consider pre-clinical data in their deliberations.

Remember you can comment on, annotate and rate any PLoS Medicine article and see the views, citations and other indications of impact of an article on that articles metrics tab.

Back to top